复发性流产 中国就医指南

Recurrent Pregnancy Loss (RPL), defined as two or more consecutive clinical pregnancy losses before 20 weeks of gestation, is a complex and emotionally devastating condition affecting individuals and couples seeking to build a family. While historically defined as three or more losses, contemporary guidelines—including those from the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Human Reproduction and Embryology (ESHRE)—recognize that evaluation should begin after two losses due to the significant psychological burden and increased likelihood of an underlying etiology. Pathogenesis is multifactorial and often idiopathic; however, identifiable causes include parental chromosomal abnormalities (e.g., balanced translocations), uterine structural anomalies (e.g., septate uterus, intrauterine adhesions), endocrine disorders (e.g., uncontrolled thyroid disease, luteal phase defect, poorly managed diabetes), autoimmune factors (notably antiphospholipid syndrome), thrombophilias (inherited or acquired), and emerging evidence implicating chronic endometritis, sperm DNA fragmentation, and immunologic dysregulation at the maternal-fetal interface. Epidemiologically, RPL affects approximately 1–2% of couples attempting conception, with prevalence rising to ~5% when including women reporting two losses. Risk factors span genetic (advanced maternal age >35, paternal age >40), anatomical (congenital Müllerian anomalies, fibroids), lifestyle (smoking, excessive caffeine, obesity, substance use), environmental (occupational toxin exposure), and comorbid medical conditions (PCOS, celiac disease, chronic hypertension). Importantly, up to 50–75% of cases remain unexplained after standard evaluation—highlighting the need for individualized, multidisciplinary care in reproductive medicine. The psychosocial impact is profound: patients frequently experience grief, anxiety, depression, marital strain, social isolation, and diminished self-worth. Many report feeling stigmatized or dismissed by healthcare providers, leading to treatment delays and reduced adherence. Quality of life metrics consistently show impairments comparable to those seen in chronic illnesses such as cancer or heart failure—underscoring RPL not merely as a reproductive issue but as a holistic health concern requiring integrated psychological, endocrinologic, immunologic, and surgical expertise. Early referral to specialized reproductive medicine departments enables comprehensive workup—including karyotyping, pelvic imaging (3D ultrasound, hysterosalpingography, hysteroscopy), hormonal profiling, thrombophilia screening, and immune markers—and facilitates timely, evidence-based interventions tailored to each patient’s unique profile.

# 复发性流产治疗方案与费用明细（生殖医学科）

一、非手术/保守/药物/理疗方案

• •适用人群：病因明确（如黄体功能不全、甲状腺功能减退、轻度免疫异常）或不明原因复发性流产（≥2次）者
• •方案明细：

- 甲状腺调节（左甲状腺素钠）：300–800元/3个月（含TSH/TPOAb复查） - 小剂量阿司匹林+低分子肝素抗凝治疗（易栓症）：2,600–6,200元/孕早期全程（含凝血全套、抗磷脂抗体谱、D-二聚体等检验费） - 免疫调节（泼尼松+羟氯喹，限APS或NK细胞升高）：1,800–4,500元/疗程（12周）

二、手术/微创/核心介入方案

• •适用人群：子宫解剖异常（纵隔子宫、宫腔粘连、黏膜下肌瘤＜4cm）
• •方案明细：

- 子宫动脉栓塞术（罕见：胎盘植入史致反复清宫后流产）：22,000–35,000元（含DSA介入费、栓塞材料、围术期抗感染）

三、特殊复杂方案

• •染色体平衡易位携带者：胚胎植入前遗传学检测（PGT-SR）+冻胚移植：38,000–52,000元/周期（含三代测序、活检、冷冻保存）
• •顽固性免疫紊乱（反复失败）：静脉注射免疫球蛋白（IVIG）联合淋巴细胞主动免疫疗法：45,000–78,000元/孕前+孕期全程

方案快速选择指南

• •预算≤5,000元/周期：首选黄体支持+甲状腺管理；
• •预算10,000–20,000元：宫腔镜手术+抗凝/免疫基础治疗；
• •高复发（≥4次）或已知遗传/免疫病因：直接启动PGT-SR或IVIG方案。